189 related articles for article (PubMed ID: 20570632)
1. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.
Hadzijusufovic E; Peter B; Gleixner KV; Schuch K; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Mirkina I; Willmann M; Valent P
Exp Hematol; 2010 Oct; 38(10):896-907. PubMed ID: 20570632
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells.
Gamperl S; Stefanzl G; Willmann M; Valent P; Hadzijusufovic E
Vet Med Sci; 2021 Jan; 7(1):57-68. PubMed ID: 32924324
[TBL] [Abstract][Full Text] [Related]
3. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
4. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
[TBL] [Abstract][Full Text] [Related]
6. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
[TBL] [Abstract][Full Text] [Related]
7. NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.
Hadzijusufovic E; Peter B; Herrmann H; Rülicke T; Cerny-Reiterer S; Schuch K; Kenner L; Thaiwong T; Yuzbasiyan-Gurkan V; Pickl WF; Willmann M; Valent P
Allergy; 2012 Jul; 67(7):858-68. PubMed ID: 22583069
[TBL] [Abstract][Full Text] [Related]
8. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
[TBL] [Abstract][Full Text] [Related]
9. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
[TBL] [Abstract][Full Text] [Related]
10. Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs.
Hey JA; Del Prado M; Cuss FM; Egan RW; Sherwood J; Lin CC; Kreutner W
Clin Exp Allergy; 1995 Oct; 25(10):974-84. PubMed ID: 8556569
[TBL] [Abstract][Full Text] [Related]
11. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.
Ghanim V; Herrmann H; Heller G; Peter B; Hadzijusufovic E; Blatt K; Schuch K; Cerny-Reiterer S; Mirkina I; Karlic H; Pickl WF; Zöchbauer-Müller S; Valent P
Blood; 2012 May; 119(18):4242-52. PubMed ID: 22438247
[TBL] [Abstract][Full Text] [Related]
12. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
[TBL] [Abstract][Full Text] [Related]
13. Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation.
Wang WT; Chen YH; Hsu JL; Leu WJ; Yu CC; Chan SH; Ho YF; Hsu LC; Guh JH
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jan; 387(1):33-45. PubMed ID: 24048439
[TBL] [Abstract][Full Text] [Related]
14. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
[TBL] [Abstract][Full Text] [Related]
16. Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
Gamperl S; Stefanzl G; Peter B; Smiljkovic D; Bauer K; Willmann M; Valent P; Hadzijusufovic E
Vet Comp Oncol; 2019 Dec; 17(4):553-561. PubMed ID: 31286638
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.
Krauth MT; Mirkina I; Herrmann H; Baumgartner C; Kneidinger M; Valent P
Clin Exp Allergy; 2009 Nov; 39(11):1711-20. PubMed ID: 19860818
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
Peter B; Gleixner KV; Cerny-Reiterer S; Herrmann H; Winter V; Hadzijusufovic E; Ferenc V; Schuch K; Mirkina I; Horny HP; Pickl WF; Müllauer L; Willmann M; Valent P
Haematologica; 2011 May; 96(5):672-80. PubMed ID: 21242189
[TBL] [Abstract][Full Text] [Related]
19. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.
Hadzijusufovic E; Rebuzzi L; Gleixner KV; Ferenc V; Peter B; Kondo R; Gruze A; Kneidinger M; Krauth MT; Mayerhofer M; Samorapoompichit P; Greish K; Iyer AK; Pickl WF; Maeda H; Willmann M; Valent P
Exp Hematol; 2008 Nov; 36(11):1461-70. PubMed ID: 18723263
[TBL] [Abstract][Full Text] [Related]
20. Effect of H1-antihistamines on histamine release from dispersed canine cutaneous mast cells.
García G; DeMora F; Ferrer L; Puigdemont A
Am J Vet Res; 1997 Mar; 58(3):293-7. PubMed ID: 9055977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
